News
Bristol Myers tops revenue expectations on strength of older drugs, shares fall
(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling brands, but failed to convince investors that newer products could drive future growth and shares fell nearly 5%.
Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...
Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...
Bristol-Myers Squibb (BMY) shares rebound after recent losses. Analysts weigh in on its value, growth potential, and updated ...
A multinational biopharmaceutical corporation, Bristol-Myers Squibb Company (NYSE:BMY) is engaged in product discovery, ...
Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...
AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...
Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia caused by a rare bone marrow ...
Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback